Novel targeted drug shows promise in advanced kidney cancer
(Dana-Farber Cancer Institute) Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2020 Category: Cancer & Oncology Source Type: news

Adding Ilixadencel Improved Outcomes in Metastatic RCC Adding Ilixadencel Improved Outcomes in Metastatic RCC
Combining intratumoral injections of ilixadencel with sunitinib improved responses in patients with newly diagnosed synchronous metastatic renal cell carcinoma in the phase 2 MERECA trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Renal Function Change Found to be a Prognostic Factor for Cancer Specific Survival in RCC
The aim of this Chinese study was to evaluate the influencing factors of perioperative renal function change and their relationship with prognosis in patients with renal cell carcinoma and tumor thrombus after nephrectomy and thrombectomy. (Source: CancerNetwork)
Source: CancerNetwork - February 9, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

SIR highlights use of percutaneous ablation for RCC
Some patients with renal cell carcinoma (RCC) can be effectively treated nonsurgically...Read more on AuntMinnie.comRelated Reading: SIR aims for more awareness of interventional radiology SIR taps Findeiss as new president SIR: Virtual reality beats fluoroscopy for catheter placement SIR: 'OK, Google -- scrub up!' SIR: Stroke treatment training program improves outcomes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 5, 2020 Category: Radiology Source Type: news

3D printing helps mummy speak from beyond the grave
Have you ever wondered what it would be like to hear a mummy speak? It's now...Read more on AuntMinnie.comRelated Reading: 3 ways to advance 3D printing in radiology AR, 3D printing make waves in cardiac care 3D printing helps unravel rare cardiac anomalies 3D printing may improve safety of upper GI surgery How can 3D printing improve kidney cancer surgery? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 24, 2020 Category: Radiology Source Type: news

UTSW researchers uncover new vulnerability in kidney cancer
(UT Southwestern Medical Center) Qing Zhang, Ph.D., and his colleagues identified a possible way to treat tumors while sparing nearby healthy tissue. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 16, 2020 Category: International Medicine & Public Health Source Type: news

B-cell enrichment predictive of immunotherapy response in melanoma, sarcoma and kidney cancer
(University of Texas M. D. Anderson Cancer Center) Multiple studies out in Nature indicate that a patient's response to immune checkpoint blockade may depend on B cells located in special structures within the tumor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 15, 2020 Category: Cancer & Oncology Source Type: news

AI can differentiate small renal masses on CT
An artificial intelligence (AI) algorithm can accurately differentiate between...Read more on AuntMinnie.comRelated Reading: 3D VR models improve kidney-sparing surgery outcomes How can 3D printing improve kidney cancer surgery? Do more CT scans lead to more kidney surgeries? CEUS shines for indeterminate small renal masses Texture analysis sorts out indecipherable kidney lesions (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 10, 2020 Category: Radiology Source Type: news

Exercise may reduce risk for cancer by as much as 25 percent
People who engaged in physical activity as recommended by the NIH were able to reduce their risk for colon and breast cancers, as well as endometrial cancer, kidney cancer, myeloma, liver cancer and non-Hodgkin lymphoma. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 26, 2019 Category: Consumer Health News Source Type: news

Risk of Kidney-cancer Recurrence Persists Beyond 5 Years After Surgery Risk of Kidney-cancer Recurrence Persists Beyond 5 Years After Surgery
The risk of recurrence in surgically treated renal-cell carcinoma (RCC) persists beyond five years after surgery, suggesting the need for continued surveillance, according to a new analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2019 Category: Consumer Health News Tags: Urology News Source Type: news

Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma
Progression - free survival longer in those receiving tivozanib as third - or fourth - line therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 23, 2019 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news

Tivozanib Bests Sorafenib in Metastatic Renal Cell Carcinoma
MONDAY, Dec. 23, 2019 -- Among patients with metastatic renal cell carcinoma, progression-free survival was longer in those receiving tivozanib versus sorafenib as third- or fourth-line therapy, according to a study published online Dec. 3 in The... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 23, 2019 Category: Pharmaceuticals Source Type: news

FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma
On April 19, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck& Co. Inc.) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 21, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Finding familiar pathways in kidney cancer
(Thomas Jefferson University) The famous cancer gene p53, which was thought to be less relevant in kidney cancer, may play a larger role than previously appreciated, suggesting new potential for treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 20, 2019 Category: International Medicine & Public Health Source Type: news

Study: Mesothelioma Patients with CD70 Protein Have Worse Prognosis
An international team of pathologists has identified a new protein often found on pleural mesothelioma tumor cells. The discovery could lead to a more accurate prognosis for patients and future treatment advances. Researchers found for the first time that mesothelioma patients expressing higher levels of the CD70 protein typically experience a much shorter survival, regardless of cell type or treatment type. “These markers might be useful for MPM [malignant pleural mesothelioma] prognostic evaluations, as well as targeted therapeutics,” the study authors wrote. “Further analyses in syngeneic mouse models...
Source: Asbestos and Mesothelioma News - December 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

3 ways to advance 3D printing in radiology
How can leaders in radiology prepare for the growing integration of 3D printing...Read more on AuntMinnie.comRelated Reading: AR, 3D printing make waves in cardiac care 3D printing helps unravel rare cardiac anomalies Radiologists rally in support of medical 3D printing ARRS: Radiologists foresee bright future for 3D printing AR, 3D printing aid presurgical planning for kidney cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 19, 2019 Category: Radiology Source Type: news

Microscopic Traces of Blood in Urine Linked to Urological Cancer Microscopic Traces of Blood in Urine Linked to Urological Cancer
Non-visible hematuria (NVH) was associated with bladder cancer (BC), upper tract urothelial carcinoma (UTUC) and kidney cancer (KC) in a systematic review and meta-analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 18, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Scientists discover a new mechanism in childhood kidney cancer
(Rockefeller University) A problem in reader proteins that identify which gene is up for expression may cause normal cells to turn malignant during development. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 18, 2019 Category: International Medicine & Public Health Source Type: news

Immune outposts inside kidney tumors predict post-surgery outcomes
(Emory Health Sciences) Patients with well-supported immune cells in their tumors are more likely to control their cancers' growth for a longer time, an observation that could guide treatment decisions after surgery for kidney cancer. In addition, the findings could help researchers expand the dramatic but sparse benefits of cancer immunotherapy to more people. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2019 Category: Cancer & Oncology Source Type: news

NHS has paid almost £600million in compensation to patients it had failed to diagnose correctly
Included in the payouts are 399 cases of misdiagnosed cancer. Dr Lisa Steen, of Cambridge, died in 2016 after saying doctors failed to spot her kidney cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - December 6, 2019 Category: Consumer Health News Source Type: news

AR, 3D printing make waves in cardiac care
CHICAGO - What are the distinct benefits of 3D printing and augmented reality...Read more on AuntMinnie.comRelated Reading: 3D printing helps unravel rare cardiac anomalies 4 core applications of cardiovascular 3D printing AR, 3D printing enhance planning for complex heart surgery AR, 3D printing aid presurgical planning for kidney cancer 3D printing gives pediatric heart surgery a boost (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 6, 2019 Category: Radiology Source Type: news

Root of childhood kidney cancer discovered
(Wellcome Trust Sanger Institute) A fundamental change in our understanding of the childhood kidney cancer Wilms' tumor is on the horizon, after the discovery of its earliest genetic root by scientists at the Wellcome Sanger Institute and their collaborators. By comparing genome sequences from normal kidney tissue and tumors, the team identified patches of normal-looking kidney tissue that in fact carried DNA changes that cause Wilms' tumor. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2019 Category: Cancer & Oncology Source Type: news

Embryonal precursors of Wilms tumor
Adult cancers often arise from premalignant clonal expansions. Whether the same is true of childhood tumors has been unclear. To investigate whether Wilms tumor (nephroblastoma; a childhood kidney cancer) develops from a premalignant background, we examined the phylogenetic relationship between tumors and corresponding normal tissues. In 14 of 23 cases studied (61%), we found premalignant clonal expansions in morphologically normal kidney tissues that preceded tumor development. These clonal expansions were defined by somatic mutations shared between tumor and normal tissues but absent from blood cells. We also found hyper...
Source: ScienceNOW - December 5, 2019 Category: Science Authors: Coorens, T. H. H., Treger, T. D., Al-Saadi, R., Moore, L., Tran, M. G. B., Mitchell, T. J., Tugnait, S., Thevanesan, C., Young, M. D., Oliver, T. R. W., Oostveen, M., Collord, G., Tarpey, P. S., Cagan, A., Hooks, Y., Brougham, M., Reynolds, B. C., Barone, Tags: Development, Medicine, Diseases reports Source Type: news

Targeted therapy better for repeat kidney cancer patients than FDA-approved counterpart
(City of Hope) Kidney cancer patients who had already tried two or three different treatments had improved chances of preventing cancer progression with an experimental drug called tivozanib compared to an alternative approved by the FDA, reports a City of Hope-led study. Published in The Lancet Oncology, the study is the first to show the benefit of tivozanib for patients with renal cell carcinoma (kidney cancer) who had received two or more previous therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 4, 2019 Category: Cancer & Oncology Source Type: news

Renal Cancer Research by Sengenics and the University of Leeds Awarded...
This collaboration will focus on discovery of novel biomarkers for renal cell carcinoma (RCC), with the goal of developing an autoantibody-based early diagnostic test for this disease(PRWeb November 26, 2019)Read the full story at https://www.prweb.com/releases/renal_cancer_research_by_sengenics_and_the_university_of_leeds_awarded_early_detection_primer_grant_funding_from_cancer_research_uk/prweb16740467.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 26, 2019 Category: Pharmaceuticals Source Type: news

Dark Waters Tells the True Story of the Lawyer Who Took DuPont to Court and Won. But Rob Bilott ’s Fight Is Far From Over
Rob Bilott, a corporate lawyer-turned-environmental crusader, doesn’t much care if he’s made enemies over the years. “I’ve been dealing with this for almost three decades,” he says. “I can’t really worry about if the people on the other side like me or not.” Bilott used to be on the other side. The Todd Haynes-directed movie Dark Waters, now playing in theaters, tells the story of how the lawyer, played by Mark Ruffalo, switched allegiances. As happened in real life, the movie depicts Ruffalo’s Bilott as a lawyer who defends large chemical companies before he is approac...
Source: TIME: Health - November 25, 2019 Category: Consumer Health News Authors: Alejandro de la Garza Tags: Uncategorized movies onetime Source Type: news

Dark Waters Tells the True Story of the Lawyer Who Took DuPont to Court and Won. But Rob Bilott ’s Fight Is Far From Over
Rob Bilott, a corporate lawyer-turned-environmental crusader, doesn’t much care if he’s made enemies over the years. “I’ve been dealing with this for almost three decades,” he says. “I can’t really worry about if the people on the other side like me or not.” Bilott used to be on the other side. The Todd Haynes-directed movie Dark Waters, now playing in theaters, tells the story of how the lawyer, played by Mark Ruffalo, switched allegiances. As happened in real life, the movie depicts Ruffalo’s Bilott as a lawyer who defends large chemical companies before he is approac...
Source: TIME: Science - November 25, 2019 Category: Science Authors: Alejandro de la Garza Tags: Uncategorized movies onetime Source Type: news

Cameron Mathison reveals how he found out he had kidney cancer
Mathison says that his mind began to race when he got the call from his doctor in September, informing him that he had kidney cancer in an exclusive interview with Dr Oz to air on Monday. (Source: the Mail online | Health)
Source: the Mail online | Health - November 23, 2019 Category: Consumer Health News Source Type: news

Martin H. Voss, MD, on Bringing Different Disciplines Together at IKCS
The medical oncologist discusses the different talks that were presented at the International Kidney Cancer Symposium in Miami. (Source: CancerNetwork)
Source: CancerNetwork - November 20, 2019 Category: Cancer & Oncology Authors: Martin H. Voss, MD Source Type: news

David Braun, MD, PhD, on the Unique Experiences at IKCS
The next gen innovator discusses the integration of fields at the International Kidney Cancer Symposium in Miami. (Source: CancerNetwork)
Source: CancerNetwork - November 20, 2019 Category: Cancer & Oncology Authors: David Braun, MD, PhD Source Type: news

From childhood cancer to mapping human development
(Academy of Medical Sciences (UK)) Professor Muzlifah Haniffa from Newcastle University and the Wellcome Sanger Institute* has won the 2019 Foulkes Foundation Medal for her ground-breaking contributions to biomedical science, it was announced today [Tuesday 19 November, 2019]. Professor Haniffa's research achievements include providing a better understanding of the developing human immune system and childhood kidney cancer, mapping the maternal-fetal interface and discovering new immune cells in the skin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 18, 2019 Category: International Medicine & Public Health Source Type: news

Mesothelioma Death from 9/11 Signals Start of Things to Come
Malignant mesothelioma has become the latest deadly cancer linked directly to the rescue, recovery and cleanup efforts following the 9/11 terrorist attack on New York City in 2001. The long-running threat has come to fruition. Eighteen years after Manhattan was engulfed in the asbestos-laced, toxic cloud of dust — caused primarily by the World Trade Center destruction — the first death from pleural mesothelioma attributed to 9/11 has been recorded. Nick Ursta, 52, from the southwestern part of Pennsylvania, died after a year-long battle with the rare cancer. Ursta, a construction worker and fireman by trade, w...
Source: Asbestos and Mesothelioma News - November 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

3D printing helps unravel rare cardiac anomalies
A 3D-printed heart model based on patient MR images helped physicians identify...Read more on AuntMinnie.comRelated Reading: 3D printing may improve safety of upper GI surgery How can 3D printing improve kidney cancer surgery? 4D flow MRI, 3D printing improve congenital heart surgery 3D printing gives pediatric heart surgery a boost 3D printing bolsters care for congenital heart disease (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 14, 2019 Category: Radiology Source Type: news

3D printing may improve safety of upper GI surgery
3D-printed models of the upper gastrointestinal (GI) tract provided several...Read more on AuntMinnie.comRelated Reading: 3D-printed head customizes neurosurgery simulation How can 3D printing improve kidney cancer surgery? 3D printing enhances chest wall reconstruction 3D printing cuts hip fracture repair time, blood loss 3D printing reduces liver transplant costs, surgery time (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 7, 2019 Category: Radiology Source Type: news

Lenvatinib, Pembrolizumab Combo Shows Promising Results in Metastatic RCC
Treatment with lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma who have already received an immune checkpoint inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - November 5, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

AVEO Oncology Announces Regulatory Update For Tivozanib In Renal Cell Carcinoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2019-- AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 4, 2019 Category: Drugs & Pharmacology Source Type: news

Renal Cell Carcinoma: 5 Things to Know Renal Cell Carcinoma: 5 Things to Know
What you need to know about the latest data on treating this common cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 25, 2019 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Pediatric Renal Cell Carcinoma Pediatric Renal Cell Carcinoma
What knowledge have we gained regarding the presentation and management of renal cell carcinoma in young patients?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 21, 2019 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Targeting a kidney cancer
(Source: ScienceNOW)
Source: ScienceNOW - October 3, 2019 Category: Science Authors: Ferrarelli, L. K. Tags: twis Source Type: news

Why the Women Most Likely to Die of Breast Cancer Have Gotten the Least Attention
How can you have a moonshot trying to cure cancer and not mention people dying of cancer?I believed the narrative that is pushed on women, that if you check your breasts and if you catch it early, you’re fine.ide class="right-rail__container right-rail__container--ad"> Lianne Kraemer had been living with metastatic breast cancer for more than a year when I met her in December 2017 at the Henry B. González Convention Center in San Antonio. Throughout the week, more than 7,000 doctors, scientists and pharmaceutical-company representatives would descend on the city for the country’s most impor...
Source: TIME: Health - October 1, 2019 Category: Consumer Health News Authors: Kate Pickert Tags: Uncategorized Breast Cancer health Source Type: news

HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
Inactivation of the VHL tumor suppressor gene is the signature initiating event in clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, and causes the accumulation of hypoxia-inducible factor 2α (HIF-2α). HIF-2α inhibitors are effective in some ccRCC cases, but both de novo and acquired resistance have been observed in the laboratory and in the clinic. Here, we identified synthetic lethality between decreased activity of cyclin-dependent kinases 4 and 6 (CDK4/6) and VHL inactivation in two species (human and Drosophila) and across diverse human ccRCC cell lines in culture and xe...
Source: Signal Transduction Knowledge Environment - October 1, 2019 Category: Science Authors: Nicholson, H. E., Tariq, Z., Housden, B. E., Jennings, R. B., Stransky, L. A., Perrimon, N., Signoretti, S., Kaelin, W. G. Tags: STKE Research Articles Source Type: news

Assessing costs of sunitinib treatment in renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2019 Category: Drugs & Pharmacology Source Type: news

Can Sorafenib be Topped in Advanced Hepatocellular Carcinoma?
New trial results examine whether there's a drug superior to sorafenib when it comes to treating kidney cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 25, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

3D virtual reality models help yield better surgical outcomes
This study was for kidney cancer, but the benefits of using 3D models for surgical planning will translate to many other types of cancer operations, such as prostate, lung, liver and pancreas.”The study ’s other authors are Dr. David Thiel, Mayo Clinic, Florida; Dr. Eric Wallen, University of North Carolina, Chapel Hill; Dr. Jennifer Linehan, John Wayne Cancer Institute, Providence Saint John’s Health Center, Santa Monica; Dr. Wesley White, University of Tennessee Medical Center, Knoxville; Dr. Ketan Badani, Icahn School of Medicine at Mount Sinai, New York; and Dr. James Porter, Swedish Urology Group, Se...
Source: UCLA Newsroom: Health Sciences - September 18, 2019 Category: Universities & Medical Training Source Type: news

The Kidney Cancer Association Announces Recipients for the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA)
A total of $1.3 million awarded to advance new treatments for kidney cancerHOUSTON– September 16, 2019– The Kidney Cancer Association (KCA) is pleased to announce the recipients of the Advanced Discovery Awards (ADA) and Young Investigator Awards (YIA). In April, the KCA approved $1.3 million in new grant funding to advance early detection and new treatments for kidney cancer. “The KCA was delighted by the high caliber of proposals received for both awards and are hopeful that this research will advance the medical community’s understanding of kidney cancer,” said Dr. Christopher Wood, Ch...
Source: Kidney Cancer Association - September 16, 2019 Category: Urology & Nephrology Source Type: news

Aveo CEO says new data eases concerns about troubled kidney cancer drug
Cambridge drugmaker Aveo Oncology is trying again with its kidney cancer drug tivozanib, disclosing new late-stage data Tuesday that sent its stock price shooting up more than 40 percent and adding $60 million to the troubled company ’s market cap.  Tivozanib was developed to treat advanced renal cell carcinoma, the most common form of kidney cancer. But Aveo has been keeping tivozanib on life support since the FDA rejected it back in 2013 due to a higher risk of death or toxicity than the industry’s… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 10, 2019 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

3D printing cuts surgery time for eye socket repair
Examining 3D-printed models based on head CT scans enabled clinicians to customize...Read more on AuntMinnie.comRelated Reading: 3D-printed head customizes neurosurgery simulation How can 3D printing improve kidney cancer surgery? 3D printing enhances chest wall reconstruction 3D printing cuts hip fracture repair time, blood loss 3D printing bolsters surgery for multiple rib fractures (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 4, 2019 Category: Radiology Source Type: news

Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer Nivolumab Plus Ipilimumab Beats Sunitinib for Advanced Kidney Cancer
Nivolumab plus ipilimumab is more effective than sunitinib as first-line treatment for patients with advanced renal-cell carcinoma (RCC), according to an extended follow-up of the ongoing CheckMate 214 trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 3, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

A Lesson in Screening For Hereditary Kidney Cancer Syndromes A Lesson in Screening For Hereditary Kidney Cancer Syndromes
This case of a renal cell carcinoma in a 30-year-old highlights the need for screening for hereditary kidney cancer syndromes in patients diagnosed with RCC at a young age.Urologic Nursing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 16, 2019 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news

Setbacks and Advances in Renal Cell Carcinoma Treatment Setbacks and Advances in Renal Cell Carcinoma Treatment
Although we have more evidence against tyrosine kinase inhibitors in the adjuvant setting, studies on immunotherapy and surveillance point toward progress.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 13, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news